Company Overview
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +0.92% |
| 6 Months: | -47.23% |
| 3 Months: | +20.33% |
| 1 Month: | +28.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)60.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 63.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NGEN NervGen Pharma Corp. PHARMA | 2.19 | -3.84 | $235.47M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 6.04M | 6.47M | 6.17M | 6.40M | 7.53M |
| Operating Income | - | -6.04M | -6.47M | -6.17M | -6.40M | -7.53M |
| EBITDA | - | -6.02M | -6.46M | -6.16M | -6.39M | -7.53M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -3.95M | -9.10M | -4.16M | -26.91M | -1.68M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -3.95M | -9.10M | -4.16M | -26.91M | -1.68M |
| Diluted EPS | - | -0.06 | -0.13 | -0.06 | - | -0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 23.03M | 17.78M | 25.18M | 25.08M |
| Operating Income | - | -23.03M | -17.78M | -25.18M | -25.08M |
| EBITDA | - | -20.09M | -17.63M | -25.09M | -25.02M |
| Interest Expense | 0 | 514.60K | 0 | - | - |
| Pretax Income | - | -20.72M | -22.38M | -24.25M | -44.12M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.72M | -22.38M | -24.25M | -44.12M |
| Diluted EPS | - | -0.39 | -0.38 | -0.36 | -0.61 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.88M | 13.24M | 19.49M | 23.21M |
| Current Assets | - | 23.15M | 12.52M | 19.01M | 22.80M |
| Cash & Equivalents | - | 22.45M | 11.66M | 17.27M | 22.07M |
| Inventory | - | - | - | - | - |
| Receivables | 64.00K | 27.03K | 250.21K | - | - |
| Total Liabilities | - | 10.41M | 15.25M | 16.91M | 19.73M |
| Current Liabilities | - | 10.22M | 15.14M | 16.90M | 19.73M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 283.45K | 197.19K | 105.60K | 8.37K |
| Total Equity | - | 13.46M | -2.01M | 2.58M | 3.48M |
| Shares Outstanding | - | 58.78M | 59.61M | 70.33M | 79.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.78M | -11.30M | -16.84M | -19.50M |
| Investing Cash Flow | - | -21.11K | -138.85K | 58.87K | 100.93K |
| Financing Cash Flow | - | 22.64M | 766.28K | 22.70M | 23.76M |
| Capital Expenditure | -45.09K | -21.11K | -141.40K | - | - |
| Free Cash Flow | - | -17.81M | -11.44M | -16.84M | -19.50M |
| Net Change in Cash | - | 4.84M | -10.67M | 5.91M | 4.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -153.9% | 1,114.0% | -941.2% | -1,268.9% |
| ROCE % | - | -168.6% | 933.9% | -973.9% | -721.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 4.96% | 4.00M | $8.20M |
| 2 | Rock Springs Capital Management, LP | 1.50% | 1.21M | $2.48M |
| 3 | DAFNA Capital Management, LLC | 1.30% | 1.05M | $2.15M |
| 4 | Ghisallo Capital Management, LLC | 1.24% | 1.00M | $2.05M |
| 5 | Armistice Capital, LLC | 0.84% | 678.00K | $1.39M |
| 6 | LMR Partners LLP | 0.74% | 600.00K | $1.23M |
| 7 | Marshall Wace LLP | 0.54% | 435.96K | $893.72K |
| 8 | UBS Group AG | 0.47% | 379.73K | $778.44K |
| 9 | Stonepine Capital Management, LLC | 0.34% | 271.68K | $556.94K |
| 10 | Jane Street Group, LLC | 0.34% | 270.75K | $555.04K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NGEN
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFB1YVFpcVNfekZleGxXdU9QZWdMS19qT09YODJrMmN5WDh4eFBKWVNuUTNodEhBdXd3T0drT2JIczVibVdjeFB6Q0lDMTk5ZC1i?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE45VnByMjBkZVhzT3VRYzIyZFhnUEV0WWxUOC1qWkpVWThlVzRlMHlTTEpwd1ZITkpUYkJEX20xMUR6VVpuNFU5dVh4Ynpmb0dJbW1XMVVfRmFqWVF0dXdCN24zdGt0UmtuZFhYc0VCS0REaGZzVWRFQm9yWjJBRzQ?oc=5" target="_bla…
NGEN Stock Price and Chart — NASDAQ:NGEN - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE82Yzlvb29sV3ZUWU5tb0ZtNDVPendKNWViTlloTUVmN1JkNVpIY0U1T1F3TXo5aktRVm54T1ZiOXlSS3BHYW9qc1NDSFZjZlRPaWlSOXQxZ1BFc0ox?oc=5" target="_blank">NGEN Stock Price and Chart — NASDAQ:NGEN</a…
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVWJNS1p4YVk2WGVYX3hKN1ozdlJQSS11dldORXNndTNXUGpwZjl3TTR6Zl9SMEoxb0haakR1cE9CSTVTbU1KYjVqc3Y1R0hQb190a19wX204NF80NVFURGtQS3V2RnZxS05WRElLclR3dmxucVlweGY0SnVlSWxXSDU3NXVodTRTZ0x4Tz…
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOcjBmSS0yM0t5V3BOMlFzbzZJaUpwdFIzMWhvVUhkT1BOYnFfbTBYa3BsdC02Vzkzci1tblkyNTNFTjZ2RzZkOXRJMDRXTTVTODI5V2kwT2U3YzVZUVZaWGJzbjdRZy0yeXVRM1hhZzBpeWZ2RzlHY2xmUHNrdmRsVTR1OFVYVW41a0dRdE…
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPNVhUcFItVnEzN01TaGtyblpOa2hXOUFRQlp0cTNBdXZ6WTJHeFN0bDdtRUdwWDRmZEdiSWNfRHNZaXdDcm5KYnBVWFFkOUdHcFRuN3pxUEJUZVlZdHZMNk9tbWNkZjBZTmRjZ1FuMG5HSWtlYlR0XzIxcFp2LUVRUTlVcE9ObWJ4N1Mtd1…
NGEN — Frequently Asked Questions
What is the current share price of NervGen Pharma Corp. (NGEN)?
As of 2026-09-19 21:16 PDT, NervGen Pharma Corp. (NGEN) trades at $2.19 on NasdaqCM. Its 52-week range is $1.59 to $5.97.
What is the market capitalisation of NGEN?
NervGen Pharma Corp. (NGEN) has a market capitalisation of $235.47M on NasdaqCM.
What is the P/E ratio of NGEN?
NGEN trades at a trailing price-to-earnings (P/E) ratio of -3.84. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 17.70.
Is NGEN a good stock to buy?
This page provides a data-driven analysis of NervGen Pharma Corp. (NGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.